These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25511758)

  • 21. Use of Chronic Kidney Disease to Enhance Prediction of Cardiovascular Risk in Those at Medium Risk.
    Chia YC; Lim HM; Ching SM
    PLoS One; 2015; 10(10):e0141344. PubMed ID: 26496190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health.
    Tomey MI; Winston JA
    Ann Glob Health; 2014; 80(1):69-76. PubMed ID: 24751567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of oxidative stress on chronic kidney disease progression.
    Putri AY; Thaha M
    Acta Med Indones; 2014 Jul; 46(3):244-52. PubMed ID: 25348188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder.
    Seifert ME; Hruska KA
    Transplantation; 2016 Mar; 100(3):497-505. PubMed ID: 26356179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis.
    Major RW; Cheng MRI; Grant RA; Shantikumar S; Xu G; Oozeerally I; Brunskill NJ; Gray LJ
    PLoS One; 2018; 13(3):e0192895. PubMed ID: 29561894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiovascular Disease In Children With Ckd].
    Corrado C; Pellitteri V; Alaimo A; Galione MA; Mongiovì R; Maringhini S
    G Ital Nefrol; 2015; 32(6):. PubMed ID: 26845213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet effects of aspirin in chronic kidney disease patients.
    Polzin A; Dannenberg L; Sansone R; Levkau B; Kelm M; Hohlfeld T; Zeus T
    J Thromb Haemost; 2016 Feb; 14(2):375-80. PubMed ID: 26644261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.
    Matsui M; Uemura S; Takeda Y; Samejima K; Matsumoto T; Hasegawa A; Tsushima H; Hoshino E; Ueda T; Morimoto K; Okamoto K; Okada S; Onoue K; Okayama S; Kawata H; Kawakami R; Maruyama N; Akai Y; Iwano M; Shiiki H; Saito Y;
    J Am Soc Nephrol; 2015 Nov; 26(11):2871-81. PubMed ID: 25788536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Ricardo AC; Anderson CA; Yang W; Zhang X; Fischer MJ; Dember LM; Fink JC; Frydrych A; Jensvold NG; Lustigova E; Nessel LC; Porter AC; Rahman M; Wright Nunes JA; Daviglus ML; Lash JP;
    Am J Kidney Dis; 2015 Mar; 65(3):412-24. PubMed ID: 25458663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin K intake and mortality in people with chronic kidney disease from NHANES III.
    Cheung CL; Sahni S; Cheung BM; Sing CW; Wong IC
    Clin Nutr; 2015 Apr; 34(2):235-40. PubMed ID: 24745600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Socio-economic disparities in the distribution of cardiovascular risk in chronic kidney disease stage 3.
    Fraser SD; Roderick PJ; McIntyre NJ; Harris S; McIntyre CW; Fluck RJ; Taal MW
    Nephron Clin Pract; 2012; 122(1-2):58-65. PubMed ID: 23548499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting cardiovascular mortality in chronic kidney disease (CKD) patients.
    Sun W; Liu D; Gong P; Shi X; Wang Y; Wang P; Gong W
    Ann Transplant; 2014 Oct; 19():513-8. PubMed ID: 25315215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
    Athyros VG; Tziomalos K; Karagiannis A
    Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeat testing is essential when estimating chronic kidney disease prevalence and associated cardiovascular risk.
    Brook MO; Bottomley MJ; Mevada C; Svistunova A; Bielinska AM; James T; Kalachik A; Harden PN
    QJM; 2012 Mar; 105(3):247-55. PubMed ID: 21964723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LDL-cholesterol lowering and renal outcomes.
    Waters DD
    Curr Opin Lipidol; 2015 Jun; 26(3):195-9. PubMed ID: 25887677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Uric acid, the kidney and cardiovascular mortality].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2015; 32 Suppl 62():. PubMed ID: 26005872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
    Heine GH; Seiler S; Fliser D
    Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine alterations and cardiovascular risk in CKD: is there a link?
    Ros S; Carrero JJ
    Nefrologia; 2013; 33(2):181-7. PubMed ID: 23511754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chronic kidney disease (CKD)--recent progress. Topics: VI. Chronic kidney disease (CKD) and associated disorders; 1. Chronic kidney disease and cardiovascular disease].
    Ueda S; Yamagishi S; Obara N; Okuda S
    Nihon Naika Gakkai Zasshi; 2012 May; 101(5):1272-7. PubMed ID: 22693846
    [No Abstract]   [Full Text] [Related]  

  • 40. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients.
    Liabeuf S; Lenglet A; Desjardins L; Neirynck N; Glorieux G; Lemke HD; Vanholder R; Diouf M; Choukroun G; Massy ZA;
    Kidney Int; 2012 Dec; 82(12):1297-303. PubMed ID: 22895515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.